Mandate

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.

The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.

Related

Vinge has advised Acrinova in connection with voluntary share redemption offering

Vinge has advised Acrinova AB (publ) in connection with its voluntary share redemption offering. The offer comprised approximately one-third of the shares in Acrinova, and the acceptance rate reached approximately 97.34 percent, representing a redemption value of approximately SEK 367.4 million.
October 27, 2025

Vinge advises Revivo Group in conjunction with the acquisition of Lejon Entreprenad

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Lejon Entreprenad, a well-established specialist company offering qualified services within surface treatment, including industrial painting, anti-corrosion painting, and FROSIO inspections.
October 27, 2025

Vinge has advised Ingka Investments on its largest forestland acquisition

Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025